p53-deficient osteosarcoma cells were shown to be resistant to doxorubicin-induced apoptosis [60], highlighting the crucial role of p53 pathway is mediating the antitumoral effects of doxorubicin. The gene discussed is TP53; the disease is osteosarcoma.